The industry is highly concentrated: in 2024 Novo Nordisk had ~59% of revenue ($31.75B) and Eli Lilly ~41% ($21.72B) ( [25] ), reflecting dominance of weekly semaglutide and dulaglutide, with Lillys tirzepatide rapidly rising
10.1016/j.expneurol.2020.113331 171 HashimH.AzminS.RazlanH.YahyaN
[5] [10] Clinical trials have demonstrated varying efficacy across the class, with weight reductions ranging from approximately 5-8% with liraglutide 3 mg to 15% with semaglutide 2.4 mg and 10-22% with tirzepatide, depending on dose
Retatrutide, a novel triple agonist of the GIP, GLP-1, and GCG receptors, has demonstrated significant hepatoprotective effects in research involving individuals with MASLD
Check the pharmacy license, check the LegitScript status, and read the refund policy